Drugs / EA-230
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07357675 | Apr 2026 → Mar 2027 expected | coronary artery disorder | EBI Anti Sepsis BV | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT02629874 Comparator | Feb → Jul 2015 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03145220 Comparator | Jun 2016 → Oct 2018 | autoinflammatory syndrome | Radboud University Medical Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EA-230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02629874 ↗ |
| Known as | Nmpf-46 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802142 ↗ |
| Modality | Peptide | “It's a linear tetrapeptide derived from the human chorionic gonadotropin hormone (hCG).” NCT02629874 ↗ |
| Route | Intravenous | “EA-230 will be administered intravenously over 2 hours” NCT02629874 ↗ |